Hologic (HOLX): Evaluating Valuation After a Steady 3-Month Share Price Climb

Market context and recent performance

Hologic (HOLX) has been quietly grinding higher this year, and the stock now sits near 75 after a steady climb over the past 3 months, supported by improving revenue and earnings growth.

See our latest analysis for Hologic.

Zooming out, Hologic’s roughly 16 percent 3 month share price return has helped rebuild confidence after a softer year. With solid revenue and earnings momentum, the stock’s longer term total shareholder returns are quietly ticking higher.

If Hologic’s steady climb has your attention, it is worth seeing how it compares with other quality names in healthcare using healthcare stocks.

With earnings growing faster than revenue and shares trading near intrinsic value estimates, investors face a key question: is Hologic still underappreciated by the market, or are future gains already priced in?

Most Popular Narrative: 2% Undervalued

With Hologic last closing at 75 and the narrative fair value at 76.5, the story leans gently supportive of further upside rather than euphoric.

The analysts have a consensus price target of 73.867 for Hologic based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of 94.0, and the most bearish reporting a price target of just 65.0.

Read the complete narrative.

Want to see why steady top line growth, rising margins and a leaner share count still argue for upside, even with a lower future multiple baked in? Dive in to uncover the specific growth path and profitability assumptions that underpin this seemingly conservative fair value.

Result: Fair Value of $76.5 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, lingering China weakness and structural tariff pressures could easily stall margin expansion and temper the seemingly conservative upside that appears to be baked into today’s narrative.

Find out about the key risks to this Hologic narrative.

Build Your Own Hologic Narrative

If you see the story differently or simply want to dig into the numbers yourself, you can build a personalized view in just minutes: Do it your way.

A great starting point for your Hologic research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for your next smart move?

Do not stop with just one opportunity, put Simply Wall Street’s powerful screener to work and line up your next batch of high conviction ideas today.

• Capture potential multi-baggers early by targeting quality up-and-comers through these 3606 penny stocks with strong financials before they hit the mainstream radar.
• Ride structural tailwinds in automation and machine learning by focusing on companies at the forefront of innovation with these 26 AI penny stocks.
• Lock in more attractive entry points by zeroing in on companies trading below intrinsic value using these 907 undervalued stocks based on cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com